迈瑞医疗：数智化方案为客户带来全方位的临床和管理价值

证券之星04-02

证券之星消息，迈瑞医疗(300760)04月01日在投资者关系平台上答复投资者关心的问题。

投资者提问：公司在年报中，花了很大的篇幅去介绍AI，请问贵公司的AI是怎么商业化的，是作为软件订阅，还是说只是卖设备时候一个锦上添花？实际并不能产生收入，如果是软件订阅，请问收费是多少，续订率是多少？如果目前只是卖设备附加的赠送项目，请问以后怎么为公司提供收入。

迈瑞医疗回复：您好，谢谢关注。全球医疗机构都在迫切追求提质增效、控费降本，医疗不可能三角的矛盾日益凸显，而迈瑞打造的以“设备+IT+AI”的数智化方案正是解决医疗机构困扰的最优解，我们的数智化方案能够为客户带来全方位的临床和管理价值。对迈瑞而言，数智化转型除了能带来一部分以软件和服务收费为主的额外流水型收入以外，更重要的是为我们的设备业务构筑更加难以被撼动的护城河，并显著提升客户粘性。谢谢。

以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。

相关 ETF

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2624018835?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-04-02 20:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2624018835","market":"hk","top_or_hot":-1,"title":"迈瑞医疗：数智化方案为客户带来全方位的临床和管理价值","media":"证券之星","content":"<html><body><p>证券之星消息，<a href=\"https://laohu8.com/S/300760\">迈瑞医疗</a>(300760)04月01日在投资者关系平台上答复投资者关心的问题。</p><p>投资者提问：公司在年报中，花了很大的篇幅去介绍AI，请问贵公司的AI是怎么商业化的，是作为软件订阅，还是说只是卖设备时候一个锦上添花？实际并不能产生收入，如果是软件订阅，请问收费是多少，续订率是多少？如果目前只是卖设备附加的赠送项目，请问以后怎么为公司提供收入。</p><p>迈瑞医疗回复：您好，谢谢关注。全球医疗机构都在迫切追求提质增效、控费降本，医疗不可能三角的矛盾日益凸显，而迈瑞打造的以“设备+IT+AI”的数智化方案正是解决医疗机构困扰的最优解，我们的数智化方案能够为客户带来全方位的临床和管理价值。对迈瑞而言，数智化转型除了能带来一部分以软件和服务收费为主的额外流水型收入以外，更重要的是为我们的设备业务构筑更加难以被撼动的护城河，并显著提升客户粘性。谢谢。</p><p>以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。</p><h2>相关 ETF</h2><p><img src=\"https://static.stockstar.com/etf/15991520260402.png\"/></p></body></html>","source":"stockstar","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>迈瑞医疗：数智化方案为客户带来全方位的临床和管理价值</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n迈瑞医疗：数智化方案为客户带来全方位的临床和管理价值\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-02 20:48 北京时间&nbsp;&nbsp;&nbsp;<a href=https://stock.stockstar.com/RB2026040200039374.shtml><strong>证券之星</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>证券之星消息，迈瑞医疗(300760)04月01日在投资者关系平台上答复投资者关心的问题。投资者提问：公司在年报中，花了很大的篇幅去介绍AI，请问贵公司的AI是怎么商业化的，是作为软件订阅，还是说只是卖设备时候一个锦上添花？实际并不能产生收入，如果是软件订阅，请问收费是多少，续订率是多少？如果目前只是卖设备附加的赠送项目，请问以后怎么为公司提供收入。迈瑞医疗回复：您好，谢谢关注。全球医疗机构都在...</p>\n\n<a href=\"https://stock.stockstar.com/RB2026040200039374.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1655091616.SGD","symbol_name":"JPMorgan Funds - China A-Share Opportunities A (acc) SGD","start_time":0,"source_url":"https://stock.stockstar.com/RB2026040200039374.shtml","article_id":"2624018835","we_media_id":"1082532455","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2624018835","pubTimestamp":1775134094,"columns":[],"sourceInfo":{"source_id":"stockstar","name":"证券之星"},"weMediaInfo":{"media_name":"证券之星","introduction":"证券之星始创于1996年，是国内领先的金融信息及综合服务平台。关注证券之星，即时获取有价值的财经资讯。","home_visible":1,"id":"1082532455","head_image":"https://community-static.tradeup.com/news/2e305640fc27210243042d09d3a7fa3f"},"summary":"全球医疗机构都在迫切追求提质增效、控费降本，医疗不可能三角的矛盾日益凸显，而迈瑞打造的以“设备+IT+AI”的数智化方案正是解决医疗机构困扰的最优解，我们的数智化方案能够为客户带来全方位的临床和管理价值。对迈瑞而言，数智化转型除了能带来一部分以软件和服务收费为主的额外流水型收入以外，更重要的是为我们的设备业务构筑更加难以被撼动的护城河，并显著提升客户粘性。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"300760":"迈瑞医疗","LU1655091616.SGD":"JPMorgan Funds - China A-Share Opportunities A (acc) SGD","LU0594300419.USD":"富达中国消费基金A","LU0359201612.USD":"贝莱德中国基金A2","LU1580142542.USD":"Blackrock Systematic China A-Share Opportunities A2 USD","LU0359202008.SGD":"Blackrock China Fund A2 SGD-H","LU1997245177.USD":"安联神洲A股基金","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","IE00B29SXG58.USD":"FSSA CHINA FOCUS \"I\" (USD) ACC","LU1820825898.SGD":"Aberdeen Standard SICAV I - China A Share Equity A Acc SGD-H","LU1023057109.AUD":"BGF CHINA \"A2\" (AUDHDG) ACC","IE00B031HY20.USD":"FSSA CHINA GROWTH \"I\" (USD) INC","LU1720050803.USD":"安联全方位中国股票基金","IE00B031J352.USD":"FSSA GREATER CHINA GROWTH \"I\" (USD) INC","LU2153592121.USD":"Aberdeen Standard SICAV I - Emerging Markets Sustainable Development Equity A Acc USD","LU0572944931.SGD":"Janus Henderson Horizon China Opportunities A2 SGD","LU0594300179.USD":"FIDELITY CHINA CONSUMER \"A\" (USD) ACC","LU1997245094.SGD":"安联神州A股基金AT Acc SGD","LU0405327148.USD":"ALLSPRING CHINA A FOCUS \"A\" (USD) ACC","LU2153591404.USD":"Aberdeen Standard SICAV I - Asian Sustainable Development Equity A Acc USD","IE0005HP3H50.USD":"GUINNESS CHINA \"C\" (USD) ACC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU1781817850.SGD":"Blackrock Systematic China A-Share Opportunities A2 SGD-H","LU2348774022.SGD":"Aberdeen Standard SICAV I - Emerging Markets Sustainable Development Equity A Acc SGD-H","LU1794554557.SGD":"Allianz All China Equity AT Acc H2-SGD","LU0405327494.USD":"ALLSPRING CHINA A FOCUS \"I\" (USD) ACC","LU1934453819.USD":"AB CHINA A SHARES EQUITY PORTFOLIO \"A\" (USD) ACC","IE0031814852.USD":"FSSA GREATER CHINA GROWTH \"I\" (USD) ACC","LU0327786744.USD":"Janus Henderson Horizon China Opportunities A2 USD","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","LU1979443071.USD":"AB CHINA A SHARES EQUITY PORTFOLIO \"AD\" (USDHDG) INC","LU1146622755.USD":"安本中国A股股票基金A Acc","LU0084288322.USD":"Natixis Asia Equity RD USD","SGXZ81163826.USD":"UNITED CHINA A-SHARES INNOVATION \"A\" (USD) ACC","LU0823426308.USD":"法巴中国股票基金","LU1734074674.USD":"NINETY ONE GSF ASIA PACIFIC FRANCHISE \"A\"(USD) ACC","SGXZ49509284.SGD":"United China A Shares Innovation A Acc SGD","LU2213484517.USD":"FRANKLIN TEMPLETON CHINA A-SHARES \"A\" (USD) ACC","LU2348773727.SGD":"Aberdeen Standard SICAV I - Asian Sustainable Development Equity A Acc SGD-H","BK0251":"专用设备","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","LU0823426480.USD":"法巴中国股票经典Dis","LU0605514214.HKD":"FIDELITY CHINA CONSUMER \"A\" (HKD) ACC","LU2424517915.HKD":"abrdn SICAV I -  ASIAN SDG EQUITY \"A\" (HKD) ACC","LU0650527681.SGD":"Fidelity China Consumer A-SGD","LU1688375341.USD":"贝莱德中国灵活股票基金","IE0008368742.USD":"首域中国增长基金I Acc"},"translate_title":"Mindray Medical: Digital and intelligent solutions bring all-round clinical and management value to customers","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300760":1.5},"content_text":"证券之星消息，迈瑞医疗(300760)04月01日在投资者关系平台上答复投资者关心的问题。投资者提问：公司在年报中，花了很大的篇幅去介绍AI，请问贵公司的AI是怎么商业化的，是作为软件订阅，还是说只是卖设备时候一个锦上添花？实际并不能产生收入，如果是软件订阅，请问收费是多少，续订率是多少？如果目前只是卖设备附加的赠送项目，请问以后怎么为公司提供收入。迈瑞医疗回复：您好，谢谢关注。全球医疗机构都在迫切追求提质增效、控费降本，医疗不可能三角的矛盾日益凸显，而迈瑞打造的以“设备+IT+AI”的数智化方案正是解决医疗机构困扰的最优解，我们的数智化方案能够为客户带来全方位的临床和管理价值。对迈瑞而言，数智化转型除了能带来一部分以软件和服务收费为主的额外流水型收入以外，更重要的是为我们的设备业务构筑更加难以被撼动的护城河，并显著提升客户粘性。谢谢。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。相关 ETF","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2624018835","isCrawlerRequest":true}